PD-1 knockout mice develop autoimmune syndromes, suggesting that the receptor PD-1 is an immune checkpoint 1,2 .
Two ligands for PD-1 are identified: B7-H1 (also known as PD-L1) and B7-DC (also known as PD-L2) [3] [4] [5] .
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B7-H1 is overexpressed on tumors, leading to immune resistance, whereas blockade of B7-H1 or PD-1 enhances antitumor immunity. B7-H1 expression in renal cancer correlates with poor clinical prognosis [6] [7] [8] The FDA approves the first 90Y-conjugated CD20-specific antibody based on higher antitumor activity in Rituxanresistant lymphomas 20 .
Two studies show for the first time that adoptive T cell therapy for patients with advanced melanoma using in vitroexpanded T cells can cause tumor regressions 24, 25 .
Bulk T cells transduced with T cell receptor genes are used to treat patients with melanoma, bypassing the need to expand tumor-specific T cells from patients with cancer 26 .
Engineered T cells expressing chimeric antigen receptors induce clinical responses in patients with B cell lymhomas 27, 28 .
A therapeutic vaccine demonstrated durable complete responses in some women with HPV-16 + vulvar intraepithelial neoplasias, a disease that normally has a spontaneous regression rate of less than 2% 15 .
The results of the first cancer vaccine to show a survival benefit in a phase 3 trial are reported. Sipileucil-T (Provenge), a dendritic cell vaccine loaded with an antigen-GM-CSF conjugate, confers a four-month overall survival advantage in men with advanced castrate-resistant prostate cancer 16 and is approved by the FDA.
A CTLA-4-specific mAb is the first agent in history to provide a survival advantage in patients with advanced melanoma in a phase 3 trial 23 .
A PD-1-specific mAb induces frequent tumor regressions in patients with advanced melanoma, renal cancer, lung cancer and colon cancer with very low rates of toxicity. Response correlates with tumor membrane expression of B7-H1 29 .
The first clear-cut benefit of Herceptin conjugated with an antimicrotubule agent was seen in patients with 'naked' Herceptin-resistant breast tumors 30 .
